Human CD8<>+<> T-Cell Responses Against the 4 Dengue Virus Serotypes Are Associated with Distinct Patterns of Protein Targets

Journal of Infectious Diseases

Volumn 212, Issue 10, 2015, Pages 1743-1751

  Weiskopf, Daniela ^a   Cerpas, Cristhiam ^c   Angelo, Michael A ^a   Bangs, Derek J ^a   Sidney, John ^a   Paul, Sinu ^a   Peters, Bjoern ^a   Sanches, Françoise P ^e   Silvera, Cassia G T ^e   Costa, Priscilla R ^e   Kallas, Esper G ^e   Gresh, Lionel ^d   De Silva, Aruna D ^a,f   Balmaseda, Angel ^c   Harris, Eva ^b   Sette, Alessandro ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Laboratorio Nacional de Virología   (Costa Rica)

^d Sustainable Sciences Institute   (Nicaragua)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

^f Genetech Research Institute   (Sri Lanka)

Author keywords

+<; sup>; Brazil; CD8<; Dengue virus; Nicaragua; Serotype specific; Sri Lanka; Sup>; T cells

Indexed keywords

CD8 ANTIGEN; CYTOKINE; EPITOPE; GAMMA INTERFERON; VIRUS PROTEIN; VIRAL PROTEIN;

ADULT; ANIMAL CELL; ARTICLE; BRAZIL; CD8+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE RESPONSE; DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; DONOR; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; FEMALE; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; NICARAGUA; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; SEROTYPE; SRI LANKA; VIRUS IMMUNITY; CLASSIFICATION; DENGUE VIRUS; IMMUNOLOGY;

BRAZIL; CD8-POSITIVE T-LYMPHOCYTES; DENGUE; DENGUE VIRUS; HUMANS; SEROGROUP; SRI LANKA; VIRAL PROTEINS;

EID: 84948421479     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv289     Document Type: Article

References (30)

1. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature 2013; 496:504-7.
2. Guzman MG, Alvarez M, Halstead SB. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol 2013; 158:1445-59.
3. Rothman AL. Immunity to dengue virus: A tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol 2011; 11:532-43.
4. Weiskopf D, Angelo MA, Sidney J, Peters B, Shresta S, Sette A. Immunodominance changes as a function of the infecting dengue virus serotype and primary versus secondary infection. J Virol 2014; 88:11383-94.
5. Weiskopf D, Yauch LE, Angelo MA, et al. Insights into HLA-restricted T cell responses in a novel mouse model of dengue virus infection point toward new implications for vaccine design. J Immunol 2011; 187:4268-79.
6. Yauch LE, Zellweger RM, Kotturi MF, et al. A protective role for dengue virus-specific CD8+ T cells. J Immunol 2009; 182:4865-73.
7. de Matos AM, Carvalho KI, Rosa DS, et al. CD8+ T Lymphocyte Expansion, Proliferation and Activation in Dengue Fever. PLoS Negl Trop Dis 2015; 9:e0003520.
8. Weiskopf D, Angelo MA, de Azeredo EL, et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci U S A 2013; 110:E2046-53.
9. Weiskopf D, Angelo MA, Bangs DJ, et al. The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes. J Virol 2015; 89:120-8.
10. Duangchinda T, DejnirattisaiW, Vasanawathana S, et al. Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc Natl Acad Sci U S A 2010; 107:16922-7.
11. Rivino L, Kumaran EA, Jovanovic V, et al. Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection. J Virol 2013; 87:2693-706.
12. Kouri G, Valdez M, Arguello L, et al. [Dengue epidemic in Nicaragua, 1985]. Rev Inst Med Trop Sao Paulo 1991; 33:365-71.
13. OhAinle M, Balmaseda A, Macalalad AR, et al. Dynamics of dengue disease severity determined by the interplay between viral genetics and serotype-specific immunity. Sci Transl Med 2011; 3:114ra28.
14. Balmaseda A, Standish K, Mercado JC, et al. Trends in patterns of dengue transmission over 4 years in a pediatric cohort study in Nicaragua. J Infect Dis 2010; 201:5-14.
15. Montoya M, Gresh L, Mercado JC, et al. Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. PLoS Negl Trop Dis 2013; 7:e2357.
16. Fernandez RJ, Vazquez S. Serological diagnosis of dengue by an ELISA inhibition method (EIM). Mem Inst Oswaldo Cruz 1990; 85:347-51.
17. Harris E, Videa E, Perez L, et al. Clinical, epidemiologic, and virologic features of dengue in the 1998 epidemic in Nicaragua. Am J Trop Med Hyg 2000; 63:5-11.
18. Mattia K, Puffer BA,Williams KL, et al. Dengue reporter virus particles for measuring neutralizing antibodies against each of the four dengue serotypes. PLoS One 2011; 6:e27252.
19. Kanakaratne N,Wahala WM, Messer WB, et al. Severe dengue epidemics in Sri Lanka, 2003-2006. Emerg Infect Dis 2009; 15:192-9.
20. Zompi S, Montoya M, Pohl MO, Balmaseda A, Harris E. Dominant cross-reactive B cell response during secondary acute dengue virus infection in humans. PLoS Negl Trop Dis 2012; 6:e1568.
21. Kim Y, Ponomarenko J, Zhu Z, et al. Immune epitope database analysis resource. Nucleic Acids Res 2012; 40:W525-30.
22. Sette A, Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and-B polymorphism. Immunogenetics 1999; 50:201-12.
23. Sidney J, Peters B, Frahm N, Brander C, Sette A. HLA class I supertypes: A revised and updated classification. BMC Immunol 2008; 9:1.
24. Umareddy I, Tang KF, Vasudevan SG, Devi S, Hibberd ML, Gu F. Dengue virus regulates type I interferon signalling in a strain-dependent manner in human cell lines. J Gen Virol 2008; 89:3052-62.
25. Dengjel J, Schoor O, Fischer R, et al. Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. Proc Natl Acad Sci U S A 2005; 102:7922-7.
26. Heaton NS, Randall G. Dengue virus-induced autophagy regulates lipid metabolism. Cell Host Microbe 2010; 8:422-32.
27. Mateo R, Nagamine CM, Spagnolo J, et al. Inhibition of cellular autophagy deranges dengue virion maturation. J Virol 2013; 87:1312-21.
28. Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: A randomised, controlled phase 2b trial. Lancet 2012; 380:1559-67.
29. Capeding MR, Tran NH, Hadinegoro SR, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: A phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 2014; 384:1358-65.
30. Villar L, Dayan GH, Arredondo-Garcia JL, et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 2015; 372:113-23.